Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Basic and clinical studies on cefmenoxime in pediatric field].

R Aoyama, Y Kakizaki, A Ohnishi

    The Japanese Journal of Antibiotics
    |October 1, 1982
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.

    Physics in medicine and biology·2016
    Same author

    Dirac versus Weyl fermions in topological insulators: Adler-Bell-Jackiw anomaly in transport phenomena.

    Physical review letters·2014
    Same author

    A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2014
    Same author

    Identification of the proto-oncogene c-fos in areas of periprosthetic osteolysis around loosened hip prostheses.

    Modern rheumatology·2014
    Same author

    Inhibitory action of (4S,6S,7R)-isomer to pheromonal activity of serricornin, (4S,6S,7S)-7-Hydroxy-4,6-dimethyl-3-nonanone.

    Journal of chemical ecology·2013
    Same author

    Reinvestigation of anhydroserricornin, (2S,3S)-2,6-diethyl-3,5-dimethyl-3,4-dihydro-2H-pyran, as a sex pheromone component for male cigarette beetle.

    Journal of chemical ecology·2013

    Cefmenoxime (CMX), a new cephalosporin, demonstrated high efficacy (94.6%) in treating various infections. Pharmacokinetic studies showed good serum levels and urinary recovery, with minimal adverse effects observed.

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Medicine

    Background:

    • Cefmenoxime (CMX) is a novel cephalosporin antibiotic.
    • Evaluation of its pharmacokinetic profile and clinical efficacy is crucial.

    Observation:

    • Pharmacokinetic data in a pediatric patient showed rapid CMX elimination with significant urinary recovery (54.7% in 6 hours).
    • Clinical trials involved 37 patients with diverse infections, including respiratory and urinary tract infections.

    Findings:

    • CMX demonstrated a high overall efficacy rate of 94.6% across treated patients.
    • Adverse reactions were infrequent, including exanthema and drug fever in one patient each.
    • Minor laboratory abnormalities included eosinophilia (2.3%) and elevated transaminases (9.8%).

    Related Experiment Videos

    Implications:

    • Cefmenoxime exhibits promising therapeutic potential for bacterial infections.
    • Its favorable efficacy and safety profile warrant further clinical investigation.
    • Understanding CMX pharmacokinetics aids in optimizing dosing regimens.